IONA Test nets pioneering biotech firm £2.5m

IONA Test nets pioneering biotech firm £2.5m

The ground-breaking non-invasive prenatal test IONA developed by AIM-listed Premaitha Health has netted the company £2.5m in its first year of commercialisation. The Manchester-based biotech specialist said the income from IONA in its first year was at the upper end of revenue expectations.

Premaitha chief executive Dr Stephen Little said: “We are very encouraged by sales in our first year of trading and particularly the growth momentum that we take into the new financial year. A broader international footprint opens up opportunities in territories with differing competitive, regulatory and intellectual property landscapes. Overall, the NIPT marketplace is developing in the way we anticipated and we believe Premaitha’s ability to offer a complete CE-marked system represents a very significant opportunity.”

See the article in full at TheBusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.